The Royal Pharmaceutical Society (RPS) has cautioned that measures to protect people against Covid-19 must be stepped up in the wake of discovery of the new variant, B.1.1.529.
It has urged members of the public to practice 'hands, face, space and ventilation' protection measures which have become less used in the last few months.
RPS director of pharmacy Robbie Turner said that though it was too early to conclude about the transmissibility or resistance of the new variant to current vaccines, quick action should be taken to protect the public.
"Each one of us must take the necessary precautions of wearing a mask in higher risk situations, maintaining social distancing wherever possible, ensuring there's appropriate ventilation indoors when meeting others and washing our hands regularly."
Encouraging people to take Covid vaccine, he said, it "is still our best defence against this virus".
Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit,
boosting the Danish company's hopes of moving beyond its image as a lifestyle drug.
The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and
celebrities worldwide.
Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165
per cent over the past two years.
The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is
$1,300 a month in the United States, for a wider range of patients.
U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new
data could lead the U.S. government to reassess that.
The Department of Health and Social Care (DHSC) has added further 28 new products to the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II
of the Drug Tariff from 1 August 2022.
PSNC said, "It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual
item' criteria and make applications to NHSBSA and DHSC, accordingly."
A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.
The Pharmaceutical Services Negotiating Committee on Tuesday (June 30) renamed itself as Community Pharmacy England, promising a "strengthened commitment" to
champion and engage with the sector.
"The name Community Pharmacy England better reflects the breadth of work that we do to both represent and support community pharmacies in England. We are their
champion," the pharmacy negotiator said.
Explaining that the rebranding exercise was in line with proposals put forward by the Review Steering Group (RSG), it said the rebrand was part of its Transforming
Pharmacy Representation (TAPR) work and that it would signal the beginning of a "new engagement strategy" to build stronger relationships with pharmacy owners.
"Becoming Community Pharmacy England is much more than a name change or a new logo, it is a driver for cultural change across our organisation.
"Our members want us to be more authoritative, representative, and influential, and rebranding gives us a clearer and stronger voice, helping us to better speak out
for community pharmacy."
The commencement of the weight management campaign has been postponed from the scheduled date of January 4, 2022 due to delay in the delivery of the campaign resource packs, Pharmaceutical Services Negotiating Committee (PSNC) stated.
After a new delivery date for the resource packs has been confirmed, PSNC will announce the new start date for the programme, which is the third mandated
health campaign for 2021/22.
A news report suggests the Department of Health and Social Care is aiming to be ready to start charging for Covid-19 tests which are currently free at the end of June.
Britain has been increasingly dependent on rapid testing to try to tackle the more-transmissible Omicron variant, which has spread rapidly through the population but is less severe.
The government has previously said it will end the universal free provision of easy-to-use lateral flow devices (LFDs) at a "later stage", with individuals and businesses bearing the cost.
The Department of Health has declined to say what the tests cost, citing commercial contracts. One source has told the Reuters news agency they can run to £30 for a pack of seven.
Free pick up from pharmacies
The tests have been made freely available to order online or pick up from local pharmacies since April. The UK Health Security Agency said that between December 30 and January 5 more than 8 million LFDs were conducted, the highest weekly figure on record.
Any prescription for Promethazine hydrochloride 10mg tablets x 56 submitted for payment to the NHSBSA for July 2022 will be reimbursed at the new price of
£17.77 not as per the price concession of £13.45 announced in the 4th concessions update published on 29 July 2022, said the Pharmaceutical Services Negotiating
Committee (PSNC).
In July 2022, PSNC received several reports from contractors unable to obtain Promethazine hydrochloride 10mg tablets (56) at the published Drug Tariff price of
£4.24.
Therefore, it submitted a request for a price concession, which was granted and subsequently published but this was later withdrawn after confirmation from the
Department of Health and Social Care (DHSC) that due to the price change mechanism, the reimbursement price for Promethazine hydrochloride 10mg tablets has
increased from £4.24 to £17.77 for July 2022.
PSNC said, "Following the price change mechanism rules, for generic drugs (excluding drugs in Category M), a price change up to and including the 8th of the month
takes effect for prescriptions dispensed in that same month. Any price change after the 8th takes place in the following month."
In response to new research that revealed inequality in menopause support with 51 per cent of women from black, Asian and minority ethnic backgrounds,
Holland & Barrett, the UK's leading health and wellness retailer, has decided to continue its menopause campaign work to make "every menopause matter".
A quarter of women (26 per cent) from minority ethnic communities say they find it difficult to access menopause support relevant to their specific backgrounds.
Alongside support from Olympian and menopause campaigner, Michelle Griffith Robinson and expert, Meera Bhogal, the retailer is launching several new initiatives
to make its information and support on menopause more inclusive by offering more diverse and personalised advice and content, tailored to different needs.
Almost a third (31 per cent) believe being able to speak to a female healthcare professional of the same ethnicity as them would have made a difference to their
menopause experience. Fifteen per cent go as far as saying that communicating in their native language would have made a positive difference.
Based on these findings, Holland and Barrett is the first retailer to launch a free, multi-language menopause online consultation service. The service will
see trained H&B menopause advisors offering guidance and symptom support in multiple languages, starting with Hindi, Urdu, Gujarati and Punjabi.
The National Pharmacy Association (NPA) has warned of multi-million financial hit for community pharmacies, while the Pharmaceutical Services Negotiating
Committee (PSNC) has renewed its calls for urgent financial support amid a looming energy bill crisis.
NPA board member, Olivier Picard, this week shared a screenshot of his estimated electricity bill on WhatsApp groups. Upon expiration of his current arrangements,
in October, his electricity bill could rise from its current £1,821 for one pharmacy to an estimated £6,914 - a near fourfold increase.
Piccard said: "This is an eye-watering rise in costs for my own pharmacies and adds to the intense financial pressure we're already under. My standing charges will
multiply by 10 and the overall cost to each pharmacy amounts to about £5,000."
His comments come just ahead of an NPA-commissioned report into pharmacy inflation which will provide an analysis of inflationary costs pressing on the community
pharmacy sector, from utilities and workforce to medicines purchasing.
The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow, country president of Pfizer, as its vice president.
"As vice president, she will support the president, Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK, in delivering his priorities.
These are improving access to medicines, delivering economic growth and helping to find solutions to big societal challenges such as climate change, AMR, and
inequalities," said ABPI in a statement.
At Pfizer, Susan leads the organisation to bring the power of innovation, data and technology together to transform healthcare and improve outcomes for patients.
She previously led Pfizer UK's vaccines business unit during the Covid-19 pandemic.
Health secretary Sajid Javid urged people to book a Covid-19 booster shot on Wednesday (December 1) as he said there were 22 confirmed cases of the Omicron
virus variant in the country.
Javid said the government believed a booster campaign would help protect against severe disease from Omicron, even if it turns out that vaccines are not as effective against the variant as previous strains of the disease.
He said he hoped to know more about Omicron within two weeks, as scientists work to understand what impact the new variant will have on transmissibility and serious disease.
"At this point in time the case numbers are very low," Javid told Sky News. "For the UK we've got 22 confirmed cases at the moment and that will go up, it will certainly go up."
Britain plans to offer all adults a Covid-19 booster shot by the end of January. Government data shows 81 per cent of the population aged over 12 have had two doses of the vaccine while 32 per cent have had a booster shot or third dose.
The General Pharmaceutical Council (GPhC) has published new reports on racism and other inequalities in pharmacy, following a series of virtual equality
roundtables.
This council organised its second equality roundtable on 18 September 2023, focussing on the topic of 'Language Barriers and Health Inequalities', and a follow-up
roundtable on 'Racism in Pharmacy: Accountability Counts' on 10 October 2023.
A wide range of pharmacy-related organisations, patient groups, equality groups, providers of translation services and software, individual pharmacists, pharmacy
technicians and wider teams from different sectors and settings attended the events.
GPhC chair, Gisela Abbam thanked speakers and attendees for listening and contributing to the important discussions around racism and language barriers, which she
said are "not purely a pharmacy problem, nor a health problem", but a "much broader" system problem.
"It is important we acknowledge that, and do what we can to tackle racism and barriers wherever we find them," she added.
In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the
highest risk of catching HIV.
The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections.
NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030.
The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating.
According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men.
However, people taking the pill must also get regular HIV testing and STI screening done every three months.
Rowlands Pharmacy has joined hands with healthcare software company HasHealth for an enhanced digital proposition to facilitate seamless delivery of a raft of
clinical services including flu and travel vaccinations.
The new system is now available across 400 Rowlands pharmacies across the UK.
The partnership comes as Rowlands Pharmacy strives to provide patients with a seamless booking experience whilst minimising time-consuming administration for pharmacy
staff, with its waiting list, medical pre-screen questionnaires and resource management capabilities, the company said in a statement.
HasHealth offers a virtual healthcare software solution that allows community pharmacies to schedule, manage, and communicate with patients easily online. It combines
its cutting-edge video technology with booking and management software, which can be adapted to any clinical service.
Nigel Swift, managing director at Rowlands Pharmacy, commented: "We pride ourselves on listening to our staff, based on feedback we knew we could do better with our
digital proposition for clinical services and flu vaccinations in particular.
Global consumer healthcare company Haleon has launched a new centre of excellence for a global leader in consumer health which will bring together world leading
academics in human behaviour and frontline healthcare professionals including community pharmacists.
Unveiled at the International Pharmaceutical Federation (FIP) Congress in 'sunny' Seville, Spain on September 20, the Centre will operate as a community of healthcare
professionals and specialists in behavioural science, health psychology and the social sciences to solve some of the most pressing everyday health challenges.
Named the Centre for Human Sciences (CHS) the initiative will be the first major programme for healthcare professionals since the Haleon's launch on July 18 as an
independent, global leader in consumer health.
The Centre's mission is to support practising health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and
communities. Combining science with deep human understanding, CHS will bring expertise in physiology together with human sciences to deliver real world-solutions
and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change.
The Centre is facilitated by Robert Horne, professor of Behavioural Medicine at UCL School of Pharmacy, who started his career as a practising pharmacist but later
chose to become a behavioural scientist when he saw an opportunity to address issues around psycho-social factors that acted as a hindrance in pharmacy practice.
Speaking to me in an exclusive three-way conversation alongside Tess Player, the global head of healthcare professional & health influencer marketing at Haleon, on
the sidelines of the FIP Congress 2022, Prof Horne expanded on what the Centre was all about and how it would work.
"We've got some good ideas, but it's not a pre-filled prescription that we're going to deliver at scale from the start. What Haleon is t
The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter.
The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2).
UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University,
analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023.
Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader
community. The sample will be structured to broadly reflect key population characteristics.
Numark Pharmacy is hosting an event today (December 4) to mark the takeover of one of the former Lloyds Pharmacy stores in Cumnock, Scotland.
It has renamed the acquired pharmacy on Tanyard as Rowlands Pharmacy Cumnock HC, which will be reopened to the community on Monday.
Rowlands Pharmacy Cumnock HC, which is the latest to reopen in Scotland, will be run by Pharmacy manager Meghan Mcewan, supported by a team of colleagues from the
local community.
At the new branch, the team will oversee prescription dispensary, vaccination services, over-the-counter medications, emergency contraception, and medication review.
Victoria Atkins MP, the new Secretary of State for Health and Social Care, visited NPA board member Sukhi Basra (L) at CliniChem pharmacy in Central London
on Thursday (16 November).
Basra was accompanied by NPA Chief Executive Mark Lyonette.
This was among Atkins' first appointments following her recent promotion in the recent Cabinet reshuffle.
Atkins met with staff and patients to explore clinical services and discuss the evolving role of the community pharmacy sector.
"Welcoming politicians and officials to my pharmacy is always a pleasure," Basra said.
Basra highlighted the opportunity to brief the Health Secretary on the latest developments, including Pharmacy First.
Margaret MacRury has stepped down from her role as superintendent director for the Rowlands Pharmacy, which has a community pharmacy network in England,Scotland and Wales with more than 450 branches.
MacRury, who served the role for a decade, will step down next month to focus on the pharmacy contract developments taking place in Scotland, Rowlands said in a statement.
She will start her new role in February 2022.
With MacRury leaving the position, Stephen Thomas, currently her deputy, will take up the role of superintendent for Rowlands. He has been with the multiple for nearly 18 years and has worked side-by-side with MacRury for the last decade.
MacRury stated: "I know Stephen will continue that commitment to protecting patients and promoting the pharmacy sector.
The British Medical Association (BMA) on Wednesday announced that 33,869 junior doctors have voted in favour of extending the industrial action and the
use of action short of strike (ASOS).
With a turnout of 62 per cent, their demand stems from the ongoing campaign for complete pay restoration. The new mandate will last till September 19, starting
on 3 April.
The BMA junior doctors committee co-chairs, Dr Robert Laurenson and Dr Vivek Trivedi, expressed frustration at the year-long strike action, highlighting the
government's avoidance tactics to tackle soaring waiting lists, access to GPs and staff shortages.
"The government should see the urgency of the situation. Rather than waste time dragging out talks, they can come forward with a credible offer on pay right now. "
"Instead, they could be celebrating a revitalised and reinvigorated junior doctor workforce, one that feels that their value has started to be restored. That
would be an achievement worth celebrating for everyone and begin to finally turn the tide on the deteriorating workforce crisis," they said.